Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Dijkstra KK"" wg kryterium: Autor


Wyświetlanie 1-18 z 18
Tytuł :
The biogenesis and characterization of mammalian microRNAs of mirtron origin.
Autorzy :
Sibley, CR
Seow, Y
Saayman, S
Dijkstra, KK
El Andaloussi, S
Weinberg, MS
Wood, MJ
Pokaż więcej
Temat :
RNA Precursors
RNA
Developmental Biology
06 Biological Sciences
introns
05 Environmental Sciences
mice
Neurons
08 Information And Computing Sciences
RNA Processing, Post-Transcriptional
Ribonuclease III/physiology
RNA Splicing
Neurons/metabolism
Ribonuclease III
MicroRNAs
animals
MicroRNAs/metabolism
RNA Precursors/metabolism
cell line
humans
RNA Interference
Źródło :
Sibley, C R, Seow, Y, Saayman, S, Dijkstra, K K, El Andaloussi, S, Weinberg, M S & Wood, M J A 2011, ' The biogenesis and characterization of mammalian microRNAs of mirtron origin ', Nucleic Acids Research, vol. 40, no. 1, pp. 438-448 . https://doi.org/10.1093/nar/gkr722
Opis pliku :
application/pdf
Tytuł :
Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy.
Autorzy :
Picco G; Wellcome Sanger Institute, Cambridge, United Kingdom.
Cattaneo CM; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands.
van Vliet EJ; Wellcome Sanger Institute, Cambridge, United Kingdom.
Crisafulli G; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.; Department of Oncology, University of Torino, Candiolo, Italy.
Rospo G; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.; Department of Oncology, University of Torino, Candiolo, Italy.
Consonni S; Wellcome Sanger Institute, Cambridge, United Kingdom.
Vieira SF; Wellcome Sanger Institute, Cambridge, United Kingdom.
Rodríguez IS; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands.
Cancelliere C; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.
Banerjee R; Wellcome Sanger Institute, Cambridge, United Kingdom.
Schipper LJ; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands.
Oddo D; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.; Department of Oncology, University of Torino, Candiolo, Italy.
Dijkstra KK; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands.
Cinatl J; Institute for Medical Virology, Goethe-University, Frankfurt am Main, Germany.
Michaelis M; School of Biosciences, University of Kent, Canterbury, United Kingdom.
Yang F
Di Nicolantonio F; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.; Department of Oncology, University of Torino, Candiolo, Italy.
Sartore-Bianchi A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy.; Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano (La Statale), Milano, Italy.
Siena S; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy.; Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano (La Statale), Milano, Italy.
Arena S; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.; Department of Oncology, University of Torino, Candiolo, Italy.
Voest EE; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands.
Bardelli A; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.; Department of Oncology, University of Torino, Candiolo, Italy.
Garnett MJ; Wellcome Sanger Institute, Cambridge, United Kingdom. .
Pokaż więcej
Corporate Authors :
Cell Model Network UK Group
Źródło :
Cancer discovery [Cancer Discov] 2021 Aug; Vol. 11 (8), pp. 1923-1937. Date of Electronic Publication: 2021 Apr 09.
Typ publikacji :
Journal Article; Comment
Czasopismo naukowe
Tytuł :
Prospective experimental treatment of colorectal cancer patients based on organoid drug responses.
Autorzy :
Ooft SN; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Weeber F; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Schipper L; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Dijkstra KK; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
McLean CM; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Kaing S; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
van de Haar J; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Prevoo W; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
van Werkhoven E; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Snaebjornsson P; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Hoes LR; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Chalabi M; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
van der Velden D; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center AMC, Amsterdam, The Netherlands.
van Leerdam M; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Boot H; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Grootscholten C; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, The Netherlands.
Bloemendal HJ; Department of Internal Medicine/Oncology, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands.
Cuppen E; Oncode Institute, Utrecht, The Netherlands; Division of Biomedical Genetics, Centre for Molecular Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands; Hartwig Medical Foundation, Amsterdam, The Netherlands.
Voest EE; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: .
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Jun; Vol. 6 (3), pp. 100103. Date of Electronic Publication: 2021 Apr 19.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma.
Autorzy :
Dijkstra KK; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands.
van den Berg JG; Department of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Weeber F; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands.
van de Haar J; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands.
Velds A; Central Genomics Facility, Netherlands Cancer Institute, Amsterdam, Netherlands.
Kaing S; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands.
Peters DDGC; Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, Netherlands.
Eskens FALM; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, Netherlands.
de Groot DA; Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands.
Tesselaar MET; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Voest EE; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands.
Pokaż więcej
Źródło :
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2021 Mar 11; Vol. 12, pp. 627819. Date of Electronic Publication: 2021 Mar 11 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Czasopismo naukowe
Tytuł :
Misuse of SARS-CoV-2 testing in symptomatic health-care staff in the UK - Authors' reply.
Autorzy :
Black JRM; Cancer Genome Evolution Research Group, University College London Cancer Institute, University College London, London, UK.
Bailey C; Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London NW1 1AT, UK.
Przewrocka J; Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London NW1 1AT, UK.
Dijkstra KK; Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London NW1 1AT, UK.
Gandhi S; Francis Crick Institute, London, UK.
Gamblin S; Francis Crick Institute, London, UK.
Barrell S; Francis Crick Institute, London, UK.
Swanton C; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK; Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London NW1 1AT, UK; University College London Hospitals NHS Trust, London, UK. Electronic address: .
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2020 Oct 24; Vol. 396 (10259), pp. 1329-1330.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't; Comment
MeSH Terms :
COVID-19*
SARS-CoV-2*
Asymptomatic Infections ; COVID-19 Testing ; Humans ; United Kingdom/epidemiology
Raport
Tytuł :
Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine.
Autorzy :
Dijkstra KK; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Monkhorst K; Department of Pathology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
Schipper LJ; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Hartemink KJ; Department of Surgery, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
Smit EF; Department of Thoracic Oncology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
Kaing S; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
de Groot R; Department of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, the Netherlands; Landsteiner Laboratory, Amsterdam University Medical Center, Location AMC, 1105 AZ Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Wolkers MC; Department of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, the Netherlands; Landsteiner Laboratory, Amsterdam University Medical Center, Location AMC, 1105 AZ Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Clevers H; Hubrecht Institute, University Medical Center Utrecht, 3584 CT Utrecht, the Netherlands; Princess Maxima Center for Pediatric Oncology, 3584 CS Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Cuppen E; Centre for Molecular Medicine, University Medical Centre Utrecht, 3584 CG Utrecht, the Netherlands; Hartwig Medical Foundation, 1098 XH Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Voest EE; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands. Electronic address: .
Pokaż więcej
Źródło :
Cell reports [Cell Rep] 2020 May 05; Vol. 31 (5), pp. 107588.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Precision Medicine*/methods
Carcinoma, Non-Small-Cell Lung/*pathology
Lung Neoplasms/*pathology
Organoids/*pathology
Humans ; Lung Neoplasms/genetics ; Mutation/genetics
Czasopismo naukowe
Tytuł :
COVID-19: the case for health-care worker screening to prevent hospital transmission.
Autorzy :
Black JRM; Cancer Genome Evolution Research Group, University College London Cancer Institute, University College London, London, UK.
Bailey C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Przewrocka J; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Dijkstra KK; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Swanton C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; University College London Hospitals NHS Trust, London, UK. Electronic address: .
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2020 May 02; Vol. 395 (10234), pp. 1418-1420. Date of Electronic Publication: 2020 Apr 16.
Typ publikacji :
Letter
MeSH Terms :
Clinical Laboratory Techniques*
Coronavirus Infections*/diagnosis
Coronavirus Infections*/epidemiology
Coronavirus Infections*/prevention & control
Coronavirus Infections*/transmission
Health Personnel*
Mass Screening*
Pandemics*/prevention & control
Pneumonia, Viral*/diagnosis
Pneumonia, Viral*/epidemiology
Pneumonia, Viral*/prevention & control
Pneumonia, Viral*/transmission
Infectious Disease Transmission, Professional-to-Patient/*prevention & control
Asymptomatic Diseases ; Betacoronavirus ; COVID-19 ; COVID-19 Testing ; Cross Infection/prevention & control ; Health Workforce ; Humans ; Quarantine ; RNA, Viral/analysis ; Real-Time Polymerase Chain Reaction ; SARS-CoV-2 ; United Kingdom
Opinia redakcyjna
Tytuł :
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
Autorzy :
Chalabi M; Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. .; Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. .; Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. .
Fanchi LF; Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.
Dijkstra KK; Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.
Van den Berg JG; Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Aalbers AG; Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Sikorska K; Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Lopez-Yurda M; Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Grootscholten C; Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Beets GL; Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.
Snaebjornsson P; Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Maas M; Radiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Mertz M; Bioimaging Facility, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Veninga V; Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.
Bounova G; Oncode Institute, Utrecht, the Netherlands.; Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Broeks A; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Beets-Tan RG; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.; Radiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
de Wijkerslooth TR; Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
van Lent AU; Gastroenterology & Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.
Marsman HA; Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.
Nuijten E; Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Kok NF; Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Kuiper M; Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Verbeek WH; Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Kok M; Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Van Leerdam ME; Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Schumacher TN; Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.
Voest EE; Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. .; Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. .; Oncode Institute, Utrecht, the Netherlands. .
Haanen JB; Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Pokaż więcej
Źródło :
Nature medicine [Nat Med] 2020 Apr; Vol. 26 (4), pp. 566-576. Date of Electronic Publication: 2020 Apr 06.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*therapy
Antineoplastic Agents, Immunological/*adverse effects
Colonic Neoplasms/*therapy
DNA Mismatch Repair/*genetics
Immunotherapy/*adverse effects
Adenocarcinoma/genetics ; Adenocarcinoma/pathology ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Immunological/administration & dosage ; Cells, Cultured ; Colonic Neoplasms/genetics ; Colonic Neoplasms/pathology ; Combined Modality Therapy ; DNA Mismatch Repair/drug effects ; Digestive System Surgical Procedures ; Drug Administration Schedule ; Feasibility Studies ; Female ; Humans ; Immunotherapy/methods ; Ipilimumab/administration & dosage ; Ipilimumab/adverse effects ; Male ; Middle Aged ; Neoadjuvant Therapy/adverse effects ; Neoadjuvant Therapy/methods ; Neoplasm Staging ; Nivolumab/administration & dosage ; Nivolumab/adverse effects ; Treatment Failure
Czasopismo naukowe
Tytuł :
Tumor organoid-T-cell coculture systems.
Autorzy :
Cattaneo CM; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.
Dijkstra KK; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.
Fanchi LF; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Kelderman S; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Kaing S; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.
van Rooij N; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
van den Brink S; Oncode Institute, Utrecht, the Netherlands.; Hubrecht Institute for Developmental Biology and Stem Cell Research-KNAW & University Medical Center Utrecht, Utrecht, the Netherlands.
Schumacher TN; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.
Voest EE; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. .; Oncode Institute, Utrecht, the Netherlands. .
Pokaż więcej
Źródło :
Nature protocols [Nat Protoc] 2020 Jan; Vol. 15 (1), pp. 15-39. Date of Electronic Publication: 2019 Dec 18.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Coculture Techniques/*methods
Neoplasms/*pathology
Organoids/*pathology
T-Lymphocytes/*cytology
Humans
Czasopismo naukowe
Tytuł :
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.
Autorzy :
Ooft SN; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Weeber F; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Dijkstra KK; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
McLean CM; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Kaing S; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
van Werkhoven E; Department of Biometrics, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
Schipper L; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Hoes L; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Vis DJ; Oncode Institute, 3521 AL Utrecht, Netherlands.; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
van de Haar J; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
Prevoo W; Department of Radiology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
Snaebjornsson P; Department of Pathology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
van der Velden D; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Klein M; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Chalabi M; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
Boot H; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
van Leerdam M; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
Bloemendal HJ; Department of Internal Medicine/Oncology, Radboud University Medical Center Nijmegen, 6525 GA Nijmegen, Netherlands.
Beerepoot LV; Department of Internal Medicine, Elisabeth-TweeSteden Hospital, 5042 AD Tilburg, Netherlands.
Wessels L; Oncode Institute, 3521 AL Utrecht, Netherlands.; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Faculty of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, 2628 CD Delft, Netherlands.
Cuppen E; Oncode Institute, 3521 AL Utrecht, Netherlands.; Division Biomedical Genetics, Centre for Molecular Medicine, University Medical Centre Utrecht, 3584 CX Utrecht, Netherlands.; Hartwig Medical Foundation, 1098 XH Amsterdam, Netherlands.
Clevers H; Oncode Institute, 3521 AL Utrecht, Netherlands.; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Centre Utrecht, 3584 CT Utrecht, Netherlands.; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, Netherlands.
Voest EE; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands. .; Oncode Institute, 3521 AL Utrecht, Netherlands.; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
Pokaż więcej
Źródło :
Science translational medicine [Sci Transl Med] 2019 Oct 09; Vol. 11 (513).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Colorectal Neoplasms/*metabolism
Colorectal Neoplasms/*pathology
Organoids/*cytology
Antineoplastic Agents/therapeutic use ; Capecitabine/therapeutic use ; Colorectal Neoplasms/drug therapy ; Female ; Fluorouracil/therapeutic use ; Humans ; Irinotecan/therapeutic use ; Oxaliplatin/therapeutic use ; Prospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Long-term expanding human airway organoids for disease modeling.
Autorzy :
Sachs N; Oncode Institute, Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands.
Papaspyropoulos A; Oncode Institute, Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands.
Zomer-van Ommen DD; Wilhelmina Children's Hospital and UMC Utrecht, Utrecht, The Netherlands.
Heo I; Oncode Institute, Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands.
Böttinger L; Oncode Institute, Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands.
Klay D; St. Antonius Hospital Nieuwegein, Nieuwegein, The Netherlands.
Weeber F; The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Huelsz-Prince G; FOM Institute AMOLF, Amsterdam, The Netherlands.
Iakobachvili N; Maastricht University, Maastricht, The Netherlands.
Amatngalim GD; Wilhelmina Children's Hospital and UMC Utrecht, Utrecht, The Netherlands.
de Ligt J; UMC Utrecht, Utrecht, The Netherlands.
van Hoeck A; UMC Utrecht, Utrecht, The Netherlands.
Proost N; Mouse Clinic for Cancer and Aging (MCCA) Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Viveen MC; UMC Utrecht, Utrecht, The Netherlands.
Lyubimova A; Oncode Institute, Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands.
Teeven L; Oncode Institute, Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands.
Derakhshan S; Wilhelmina Children's Hospital and UMC Utrecht, Utrecht, The Netherlands.
Korving J; Oncode Institute, Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands.
Begthel H; Oncode Institute, Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands.
Dekkers JF; Oncode Institute, Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands.
Kumawat K; Wilhelmina Children's Hospital and UMC Utrecht, Utrecht, The Netherlands.
Ramos E; Hubrecht Organoid Technology, Utrecht, The Netherlands.
van Oosterhout MF; St. Antonius Hospital Nieuwegein, Nieuwegein, The Netherlands.
Offerhaus GJ; UMC Utrecht, Utrecht, The Netherlands.
Wiener DJ; Oncode Institute, Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands.
Olimpio EP; FOM Institute AMOLF, Amsterdam, The Netherlands.
Dijkstra KK; The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Smit EF; The Netherlands Cancer Institute, Amsterdam, The Netherlands.
van der Linden M; Wilhelmina Children's Hospital and UMC Utrecht, Utrecht, The Netherlands.
Jaksani S; Hubrecht Organoid Technology, Utrecht, The Netherlands.
van de Ven M; Mouse Clinic for Cancer and Aging (MCCA) Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Jonkers J; Mouse Clinic for Cancer and Aging (MCCA) Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Rios AC; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Voest EE; The Netherlands Cancer Institute, Amsterdam, The Netherlands.
van Moorsel CH; St. Antonius Hospital Nieuwegein, Nieuwegein, The Netherlands.
van der Ent CK; Wilhelmina Children's Hospital and UMC Utrecht, Utrecht, The Netherlands.
Cuppen E; UMC Utrecht, Utrecht, The Netherlands.
van Oudenaarden A; Oncode Institute, Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands.
Coenjaerts FE; UMC Utrecht, Utrecht, The Netherlands.
Meyaard L; Wilhelmina Children's Hospital and UMC Utrecht, Utrecht, The Netherlands.
Bont LJ; Wilhelmina Children's Hospital and UMC Utrecht, Utrecht, The Netherlands.
Peters PJ; Maastricht University, Maastricht, The Netherlands.
Tans SJ; FOM Institute AMOLF, Amsterdam, The Netherlands.
van Zon JS; FOM Institute AMOLF, Amsterdam, The Netherlands.
Boj SF; Hubrecht Organoid Technology, Utrecht, The Netherlands.
Vries RG; Hubrecht Organoid Technology, Utrecht, The Netherlands.
Beekman JM; Wilhelmina Children's Hospital and UMC Utrecht, Utrecht, The Netherlands.
Clevers H; Oncode Institute, Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands .; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Pokaż więcej
Źródło :
The EMBO journal [EMBO J] 2019 Feb 15; Vol. 38 (4). Date of Electronic Publication: 2019 Jan 14.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*pathology
Cystic Fibrosis/*pathology
Epithelial Cells/*pathology
Organ Culture Techniques/*methods
Organoids/*pathology
Respiratory Syncytial Virus Infections/*pathology
Respiratory System/*pathology
Animals ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/metabolism ; Cells, Cultured ; Cystic Fibrosis/metabolism ; Cystic Fibrosis Transmembrane Conductance Regulator/metabolism ; Disease Models, Animal ; Drug Screening Assays, Antitumor ; Epithelial Cells/metabolism ; Female ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Male ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Organoids/metabolism ; Respiratory Syncytial Virus Infections/virology ; Respiratory Syncytial Viruses/isolation & purification ; Respiratory System/metabolism ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids.
Autorzy :
Dijkstra KK; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
Cattaneo CM; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
Weeber F; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
Chalabi M; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands; Department of Gastroenterologic Oncology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
van de Haar J; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
Fanchi LF; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
Slagter M; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
van der Velden DL; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
Kaing S; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
Kelderman S; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
van Rooij N; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
van Leerdam ME; Department of Gastroenterologic Oncology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
Depla A; Department of Gastroenterology and Hepatology, EC Slotervaart Hospital, 1066 CX Amsterdam, the Netherlands.
Smit EF; Department of Thoracic Oncology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
Hartemink KJ; Department of Surgery, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
de Groot R; Department of Hematopoeisis, Sanquin Research, 1066 CX Amsterdam, the Netherlands.
Wolkers MC; Department of Hematopoeisis, Sanquin Research, 1066 CX Amsterdam, the Netherlands; Landsteiner Laboratory, Amsterdam Medical Center, 1105 AZ Amsterdam, the Netherlands.
Sachs N; Hubrecht Institute, University Medical Center Utrecht, 3584 CT Utrecht, the Netherlands.
Snaebjornsson P; Department of Pathology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
Monkhorst K; Department of Pathology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
Haanen J; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
Clevers H; Hubrecht Institute, University Medical Center Utrecht, 3584 CT Utrecht, the Netherlands; Princess Maxima Center for Pediatric Oncology, 3584 CS Utrecht, the Netherlands; Oncode Institute, the Netherlands.
Schumacher TN; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands; Oncode Institute, the Netherlands.
Voest EE; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands. Electronic address: .
Pokaż więcej
Źródło :
Cell [Cell] 2018 Sep 06; Vol. 174 (6), pp. 1586-1598.e12. Date of Electronic Publication: 2018 Aug 09.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Leukocytes, Mononuclear/*cytology
T-Lymphocytes/*immunology
Aged ; Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Non-Small-Cell Lung/pathology ; Cell Culture Techniques ; Coculture Techniques ; Colorectal Neoplasms/metabolism ; Colorectal Neoplasms/pathology ; Female ; Humans ; In Vitro Techniques ; Interferon-gamma/pharmacology ; Leukocytes, Mononuclear/metabolism ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Lymphocyte Activation/drug effects ; Male ; Middle Aged ; T-Lymphocytes/cytology ; T-Lymphocytes/drug effects ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery.
Autorzy :
Weeber F; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Noord-Holland 1066CX, the Netherlands.
Ooft SN; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Noord-Holland 1066CX, the Netherlands.
Dijkstra KK; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Noord-Holland 1066CX, the Netherlands.
Voest EE; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Noord-Holland 1066CX, the Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Noord-Holland 1066CX, the Netherlands; Foundation Hubrecht Organoid Technology (HUB), Utrecht, Utrecht 3584CM, the Netherlands; Cancer Genomics.nl, Utrecht, Utrecht 3584 CG, the Netherlands. Electronic address: .
Pokaż więcej
Źródło :
Cell chemical biology [Cell Chem Biol] 2017 Sep 21; Vol. 24 (9), pp. 1092-1100. Date of Electronic Publication: 2017 Jul 27.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Drug Discovery*
Models, Biological*
Neoplasms/*therapy
Animals ; Antineoplastic Agents/therapeutic use ; CRISPR-Cas Systems ; Cell Culture Techniques ; Cystic Fibrosis/therapy ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Cystic Fibrosis Transmembrane Conductance Regulator/metabolism ; Humans ; Neoplasms/drug therapy ; Neoplasms/pathology ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors: A Review.
Autorzy :
Dijkstra KK; Division of Molecular Oncology, Antoni van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Voabil P; Division of Immunology, Antoni van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Schumacher TN; Division of Immunology, Antoni van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Voest EE; Division of Molecular Oncology, Antoni van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Pokaż więcej
Źródło :
JAMA oncology [JAMA Oncol] 2016 Nov 01; Vol. 2 (11), pp. 1490-1495.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Transcriptome*
Antineoplastic Agents/*therapeutic use
Biomarkers, Tumor/*metabolism
Immunologic Factors/*therapeutic use
Neoplasms/*drug therapy
Antineoplastic Agents/pharmacology ; Biomarkers, Tumor/genetics ; Genomics ; Humans ; Immunologic Factors/pharmacology ; Neoplasms/immunology ; Neoplasms/metabolism ; Patient Selection ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases.
Autorzy :
Weeber F; Department of Molecular Oncology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands;
van de Wetering M; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences, 3584 CT Utrecht, The Netherlands; Cancer Genomics.nl, 3584 CG Utrecht, The Netherlands; Foundation Hubrecht Organoid Technology (HUB), 3584 CT, Utrecht, The Netherlands;
Hoogstraat M; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands;
Dijkstra KK; Department of Molecular Oncology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands;
Krijgsman O; Department of Molecular Oncology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands;
Kuilman T; Department of Molecular Oncology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands;
Gadellaa-van Hooijdonk CG; Department of Radiotherapy, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands;
van der Velden DL; Department of Molecular Oncology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands;
Peeper DS; Department of Molecular Oncology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands;
Cuppen EP; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences, 3584 CT Utrecht, The Netherlands; Cancer Genomics.nl, 3584 CG Utrecht, The Netherlands; Department of Medical Genetics, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands;
Vries RG; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences, 3584 CT Utrecht, The Netherlands; Cancer Genomics.nl, 3584 CG Utrecht, The Netherlands; Foundation Hubrecht Organoid Technology (HUB), 3584 CT, Utrecht, The Netherlands;
Clevers H; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences, 3584 CT Utrecht, The Netherlands; Cancer Genomics.nl, 3584 CG Utrecht, The Netherlands; Foundation Hubrecht Organoid Technology (HUB), 3584 CT, Utrecht, The Netherlands; Department of Molecular Genetics, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands; .
Voest EE; Department of Molecular Oncology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands; Cancer Genomics.nl, 3584 CG Utrecht, The Netherlands; Foundation Hubrecht Organoid Technology (HUB), 3584 CT, Utrecht, The Netherlands; Department of Medical Oncology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands .
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2015 Oct 27; Vol. 112 (43), pp. 13308-11. Date of Electronic Publication: 2015 Oct 12.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cell Culture Techniques/*methods
Colorectal Neoplasms/*genetics
Genetic Variation/*genetics
Neoplasm Metastasis/*genetics
Organoids/*cytology
Organoids/*growth & development
Antineoplastic Protocols/standards ; Base Sequence ; Colorectal Neoplasms/drug therapy ; Genes, Neoplasm/genetics ; Humans ; Molecular Sequence Data ; Organoids/chemistry ; Precision Medicine/methods ; Sequence Analysis, DNA
Czasopismo naukowe
Tytuł :
TH17 differentiation capacity develops within the first 3 months of life.
Autorzy :
Dijkstra KK; Center for Molecular and Cellular Intervention, Laboratory for Translational Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
Hoeks SB; Center for Molecular and Cellular Intervention, Laboratory for Translational Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
Prakken BJ; Center for Molecular and Cellular Intervention, Laboratory for Translational Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
de Roock S; Center for Molecular and Cellular Intervention, Laboratory for Translational Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: .
Pokaż więcej
Źródło :
The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2014 Mar; Vol. 133 (3), pp. 891-4.e5. Date of Electronic Publication: 2013 Nov 01.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Cell Differentiation*
Fetal Blood/*immunology
Th17 Cells/*cytology
Age Factors ; Antigen-Presenting Cells/physiology ; Cytokines/biosynthesis ; Humans ; Infant
Raport
Tytuł :
Patterns and predictors of atypical language representation in epilepsy.
Autorzy :
Dijkstra KK; Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Neurology & Neurosurgery F02.2.30, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Ferrier CH
Pokaż więcej
Źródło :
Journal of neurology, neurosurgery, and psychiatry [J Neurol Neurosurg Psychiatry] 2013 Apr; Vol. 84 (4), pp. 379-85. Date of Electronic Publication: 2012 Sep 01.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Language*
Epilepsy/*physiopathology
Functional Laterality/*physiology
Adolescent ; Adult ; Age of Onset ; Aged ; Child ; Child, Preschool ; Dominance, Cerebral/physiology ; Epilepsy/epidemiology ; Epilepsy/pathology ; Humans ; Middle Aged ; Reference Values ; Young Adult
Czasopismo naukowe
Tytuł :
The biogenesis and characterization of mammalian microRNAs of mirtron origin.
Autorzy :
Sibley CR; Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, OX1 3QX, UK.
Seow Y
Saayman S
Dijkstra KK
El Andaloussi S
Weinberg MS
Wood MJ
Pokaż więcej
Źródło :
Nucleic acids research [Nucleic Acids Res] 2012 Jan; Vol. 40 (1), pp. 438-48. Date of Electronic Publication: 2011 Sep 13.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
RNA Interference*
MicroRNAs/*metabolism
RNA Precursors/*metabolism
Animals ; Cell Line ; Humans ; Introns ; Mice ; Neurons/metabolism ; RNA Processing, Post-Transcriptional ; RNA Splicing ; Ribonuclease III/physiology
Czasopismo naukowe
    Wyświetlanie 1-18 z 18

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies